Activation of CAR leads to alteration in the expression of phase 1 and phase 2 drug metabolizing enzymes, hepatocyte hypertrophy, and proliferation, and after chronic exposure, hepatocellular adenomas and carcinomas [54]. This evidence concerns the gene NR1I3 and carcinoma.